Regeneron Pharmaceuticals (REGN) Debt Ratio (2014 - 2026)

Regeneron Pharmaceuticals' Debt Ratio history runs 9 years deep, the most recent figure standing at 0.05 for Q1 2026.

• On a quarterly basis, Debt Ratio fell 8.07% year-over-year to 0.05 in Q1 2026; TTM through Mar 2026 was 0.05, a 8.07% decrease from a year earlier, with the FY2025 full-year figure at 0.05, down 6.83% from the prior year.
• Debt Ratio slipped to 0.05 in Q1 2026 per REGN's latest filing, from 0.05 in the prior quarter.
• Across five years, Debt Ratio topped out at 0.08 in Q1 2022 and bottomed at 0.05 in Q1 2026.
• The 5-year median for Debt Ratio is 0.06 (2024), against an average of 0.06.
• Across the five-year window, Debt Ratio tumbled 32.5% in 2022 and retreated 5.51% in 2025, its largest moves.
• Year by year, Debt Ratio stood at 0.07 in 2022, then decreased by 11.62% to 0.06 in 2023, then retreated by 12.33% to 0.05 in 2024, then retreated by 6.83% to 0.05 in 2025, then decreased by 0.74% to 0.05 in 2026.
• Per Business Quant, the three latest REGN Debt Ratio figures stand at 0.05 (Q1 2026), 0.05 (Q4 2025), and 0.05 (Q3 2025).